No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients

Haematologica

Volumn 92, Issue 9, 2007, Pages 1208-1215

  Sundin, Mikael ^a,b   Ringdén, Olle ^a,b   Sundberg, Berit ^a   Nava, Silvia ^a   Götherström, Cecilia ^a   Le Blanc, Katarina ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cross match; Humoral; Immunogenicity; Rejection

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; ALLOANTIGEN; BLOOD GROUP ANTIGEN; BUSULFAN; CELL ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CHILD; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL CALF SERUM; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYME CELL; PROTEIN EXPRESSION; STROMA CELL;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; CATTLE; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; CHILD; FEMALE; FETAL BLOOD; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOGLOBULINS; IMMUNOPHENOTYPING; INFANT; ISOANTIBODIES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STROMAL CELLS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 36348946918     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11446     Document Type: Article

References (55)

1. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997; 64:278-94.
2. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-47.
3. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization or cells with osteogenic potential from human marrow. Bone 1992;13:81-8.
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7.
5. Prockop DJ, Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
6. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties or differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-6.
7. Zhang W, Ge W, Li C, You S, L Liao, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004;13:263-71.
8. +-derived and monocyte-derived dendritic cells. J Immunol 2006;177:2080-7.
9. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-22.
10. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105:2821-7.
11. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-9.
12. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-13.
13. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305:33-41.
14. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independendy of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
15. Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant 2006;37:1051-9.
16. Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005;7:36-45.
17. Le Blanc K, Ringden O. Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation. Haematologica 2005;90:438.
18. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
19. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81:1390-7.
20. Horwitz EM, MSC: a coming of age in regenerative medicine. Cytotherapy 2006;8:194-5.
21. Tyndall A, LeBlanc K, Stem cells and rheumatology: update on adult stem cell therapy in autoimmune diseases. Arthritis Rheum 2006;55:521-5.
22. Koc ON, Peters C, Aubourg P, Raghavan S, Dyhouse S, DeGasperi R, et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and eeroxisomal storage diseases. Exp Hematol 1999;27:1675-81.
23. von Melchner H, Bartlett PF. Mechanisms of early allogeneic marrow graft rejection. Immunol Rev 1983; 71:31-56.
24. Warner JF, Dennert G. Bone marrow graft rejection as a function of antibody-directed natural killer cells. J Exp Med 1985;161:563-76.
25. Murphy WJ, Kumar V, Bennett M, Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med 1987;166:1499-509.
26. Storb R, Epstein RB, Rudolph RH, Thomas ED. The effect of prior transfusion on marrow grafts between histocompatible canine siblings. J Immunol 1970;105:627-33.
27. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977;296:61-6.
28. Claas FH, van Rood JJ, Warren RP, Weiden PL, Su PJ, Storb R. The detection of non-HLA antibodies and their possible role in bone marrow graft rejection. Transplant Proc 1979; 11:423-6.
29. Gluckman JC, Gluckman E, Azogui O, Guillet J, Baldwin WM, Devergie A, et al. Monocytotoxic antibodies after bone marrow transplantation in aplastic anemia. Transplantation 1982; 33:599-602.
30. Stussi G, Halter J, Schanz U, Seebach JD. ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. Transfus Apher Sci 2006;35:59-69.
31. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83:2723-30.
32. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005;105:879-85.
33. Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24:823-30.
34. Storb R, Deeg HJ, Fisher L, Appelbaum F, Buckner CD, Bensinger W, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988;71:293-8.
35. Ringden O, Remberger M, Persson U, Ljungman P, Aldener A, Andstrom E, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995;15:619-25.
36. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 2002;51:120-7.
37. Pei R, Wang G, Tarsitani C, Rojo S, Chen T, Takemura S, et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998;59:313-22.
38. Avrameas S, Ternynck T. The cross-linking of proteins with glutaraldehyde and its use tor the preparation of immunoadsorbents. Immunochemistry 1969;6:53-66.
39. Sieff C, Bicknell D, Caine G, Robinson J, Lam G, and Greaves MF. Changes in cell surface antigen expression during hemopoietic differentiation. Blood 1982;60:703-13.
40. Eliopoulos N, Stage J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005; 106:4057-65.
41. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108:2114-20.
42. Hernandez-Fuentes MP, Baker RJ, Lechler RI. The alloresponse. Rev Immunogenet 1999;1:282-96.
43. Sumitran-Holgersson S, HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant 2001;16:897-904.
44. Perreault C, Giasson M, Gyger M, Belanger R, David M, Bonny Y, et al. Serum immunoglobulin levels following allogeneic bone marrow transplantation. Blut 1985;51:137-42.
45. Griffith LM, McCoy JP, Bolan CD Jr, Stroncek DF Pickett, AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128:668-75.
46. van Tol MJ, Gerritsen EJ, de Lange GG, van Leeuwen AM, Jol-van der Zjjde CM, Oudeman-Gruber NJ, et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 1996;87:818-26.
47. Lapierre V, Auperin A, Tayebi H, Chabod J, Saas P, Michalet M, et al. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood 2002;100:1484-9.
48. Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. Multipotent mesenchymal stromal cells induce antibody secretion in human B cells Scand J Immunol 2007;65:336-43
49. Ge X, Ericzon BG, Nowak G, Horstrom H, Broome U, Sumitran-Holgersson S. Are preformed antibodies to biliary epithelial cells of clinical importance in liver transplantation? Liver Transplant 2003;9:1191-8.
50. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004;9:747-56.
51. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNaU RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932-7.
52. Jefferis R, Pound J, Lund J, Goodall M. Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article. Ann Biol Clin (Paris) 1994;52:57-65.
53. Cunningham-Rundles C. Naturally occurring autologous anti-idiotypic antibodies. Participation in immune complex formation in selective IgA deficiency. J Exp Med 1982;155:711-9.
54. Dise T, Brunell PA. Anti-bovine antibody in human sera as a cause of non-specificity in enzyme immunoassay. J Clin Microbiol 1987;25:987-90.
55. Kletter B, Gery I, Freier S, Davies AM. Immune responses of normal infants to cow milk. I. Antibody type and kinetics of production. Int Arch Allergy Appl Immunol 1971;40:656-66.